Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T0HM
|
|||
| Drug Name |
PMID28270021-Compound-WO2010077680 109
|
|||
| Indication | Chronic pain [ICD-11: MG30; ICD-10: R52.1, R52.2; ICD-9: 338.2, 780] | Patented | [1] | |
| Neuropathic pain [ICD-11: 8E43.0] | Patented | [1] | ||
| Pruritus [ICD-11: EC90; ICD-10: L29, L29.9] | Patented | [1] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Patented | [1] | ||
| Thymic cancer [ICD-11: 2C27; ICD-10: C37] | Patented | [1] | ||
| Company |
VM PHARMA LLC WU, Jay Jie-Qiang WANG, Ling
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tropomyosin-related kinase A (TrkA) | Target Info | Antagonist | [1] |
| Target's Patent Info | Tropomyosin-related kinase A (TrkA) | Target's Patent Info | [1] | |
| KEGG Pathway | MAPK signaling pathway | |||
| Endocytosis | ||||
| Apoptosis | ||||
| Neurotrophin signaling pathway | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Pathways in cancer | ||||
| Transcriptional misregulation in cancer | ||||
| Thyroid cancer | ||||
| Central carbon metabolism in cancer | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Neurotrophic factor-mediated Trk receptor signaling | |||
| Reactome | Frs2-mediated activation | |||
| ARMS-mediated activation | ||||
| NGF-independant TRKA activation | ||||
| PI3K/AKT activation | ||||
| WikiPathways | MAPK Signaling Pathway | |||
| BDNF signaling pathway | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| NGF signalling via TRKA from the plasma membrane | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.